AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 4.98 |
|---|---|
| Change | -0.110 2.209% |
| 52 W H/L (in USD) | 11.300/4.299 |
| EBITDA (in USD) | -50.509M |
| PE Ratio | -- |
| Volume | 101025 |
| Diluted Eps TTM | -2.04 |
| Total Assets (in USD) | 104.794M |
|---|---|
| Total Liabilities (in USD) | 65.47M |
| Revenue TTM (in USD) | 56.651M |
| Cash (in USD) | 75.708M |
| Market Cap (in USD) | 190.496 M |
| Revenue Per Share TTM | 2.172 |
| Gross Profit TTM (in USD) | 48.34M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
CVRx Inc
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Employees: 223
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Nadim Yared | CEO, Pres & Director | 1968 |
| 2. | Mr. Jared Oasheim | Chief Financial Officer | 1983 |
| 3. | Mr. Paul Verrastro | Chief Marketing & Strategy Officer | 1963 |
| 4. | Mr. Paul Pignato | VP of Operations | NA |
| 5. | Mr. Craig Palmer | Sr. VP of US Sales | 1977 |
| 6. | Mr. Kevin Hykes | President, CEO & Director | 1966 |
| 7. | Mr. Jared Oasheim | Chief Financial Officer | 1984 |
| 8. | Mr. Paul Pignato | Vice President of Operations | NA |
| 9. | Ms. Jonelle R. Burnham | Vice President & General Counsel | 1971 |
| 10. | Mr. Craig Palmer | Senior Vice President of US Sales | 1977 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
+1.950 2.199% | 89.355 | 25.970 | 17.241 | 3.570 | 3.200 | 3.805 | 16.753 |
|
SYK
Stryker Corporation |
+2.640 0.857% | 309.24 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
+0.940 1.169% | 81.3 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
+0.160 0.342% | 47.25 | 31.490 | 17.241 | 4.407 | 3.650 | 4.878 | 19.194 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -53.324M | -59.91M | -41.052M | -41.319M | -42.987M |
| Minority Interest | - | - | - | - | - |
| Net Income | -53.306M | -59.965M | -41.199M | -41.428M | -43.078M |
| Selling General Administrative | 88.473M | 91.317M | 61.604M | 50.045M | 27.863M |
| Gross Profit | 48.34M | 42.958M | 33.039M | 17.47M | 9.396M |
| Reconciled Depreciation | 0.756M | 0.619M | 0.521M | 0.412M | 0.168M |
| Ebit | - | -55.513M | -43.103M | -42.527M | -25.968M |
| Ebitda | -51.265M | -54.894M | -43.103M | -41.154M | -40.768M |
| Depreciation And Amortization | - | 0.619M | 0.522M | 1.373M | -14.8M |
| Operating Income | -51.265M | -59.49M | -43.103M | -42.527M | -25.968M |
| Other Operating Expenses | 107.916M | 110.782M | 82.398M | 64.996M | 39.004M |
| Interest Expense | 5.827M | 4.397M | 1.799M | 0.165M | 2.219M |
| Tax Provision | -0.018M | 0.055M | 0.136M | 0.109M | 0.091M |
| Interest Income | - | - | - | - | - |
| Net Interest Income | -5.827M | -4.397M | -1.385M | -0.165M | -2.219M |
| Income Tax Expense | 0.018M | 0.055M | -0.147M | 0.109M | 0.091M |
| Total Revenue | 56.651M | 51.292M | 39.295M | 22.469M | 13.036M |
| Total Operating Expenses | 99.605M | 102.448M | 76.142M | 59.997M | 35.364M |
| Cost Of Revenue | 8.311M | 8.334M | 6.256M | 4.999M | 3.64M |
| Total Other Income Expense Net | -2.059M | -0.42M | 2.051M | 1.208M | -17.019M |
| Net Income From Continuing Ops | -53.306M | -59.965M | -42.572M | -41.428M | -43.078M |
| Net Income Applicable To Common Shares | - | - | - | -41.428M | -43.078M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 104.794M | 133.414M | 115.229M | 124.937M | 152.548M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.069M | 2.505M | 2.987M | 4.223M | 2.585M |
| Total Liab | 65.47M | 62.359M | 39.282M | 15.757M | 6.589M |
| Total Stockholder Equity | 39.324M | 71.055M | 75.947M | 109.18M | 145.959M |
| Other Current Liab | 9.484M | 7.763M | 5.98M | 6.147M | 5.398M |
| Common Stock | 0.263M | 0.253M | 0.209M | 0.207M | 0.204M |
| Capital Stock | 0.263M | 0.253M | 0.209M | 0.207M | 0.204M |
| Retained Earnings | -590.652M | -537.346M | -477.381M | -436.182M | -394.754M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 0.027M | 0.026M |
| Cash | 75.708M | 105.933M | 90.569M | 106.194M | 142.072M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 13.317M | 10.762M | 7.864M | 8.088M | 5.908M |
| Current Deferred Revenue | - | - | -0.231M | - | - |
| Net Debt | -24.918M | -55.501M | -59.956M | -99.108M | -142.072M |
| Short Term Debt | - | 0.282M | 0.231M | 0.222M | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 50.79M | 50.432M | 30.613M | 7.086M | - |
| Other Stockholder Equity | 629.916M | 608.354M | 553.326M | 545.362M | 388.159M |
| Property Plant Equipment | - | - | - | 1.698M | 1.425M |
| Total Current Assets | 101.647M | 129.813M | 112.09M | 122.878M | 151.097M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 10.665M | 9.268M | 7.551M | 5.504M | 2.56M |
| Long Term Debt | 49.514M | 49.273M | 29.222M | 6.747M | - |
| Inventory | 12.205M | 12.107M | 10.983M | 6.957M | 3.88M |
| Accounts Payable | 3.833M | 2.582M | 1.884M | 1.719M | 0.51M |
| Accumulated Other Comprehensive Income | -0.203M | -0.206M | -0.207M | -0.207M | -0.198M |
| Non Currrent Assets Other | 0.026M | 0.027M | 0.027M | 0.027M | 0.026M |
| Non Current Assets Total | 3.147M | 3.601M | 3.139M | 2.059M | 1.451M |
| Capital Lease Obligations | 0.99M | 1.159M | 1.391M | 0.117M | - |
| Long Term Debt Total | - | - | - | 6.747M | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | - | -1.361M | -0.501M | -0.685M | -1.183M |
| Total Cashflows From Investing Activities | -0.58M | -1.361M | -0.591M | -0.685M | -1.183M |
| Total Cash From Financing Activities | 10.52M | 55.87M | 23.984M | 7.493M | 111.883M |
| Net Income | -53.306M | -59.965M | -41.199M | -41.428M | -43.078M |
| Change In Cash | -30.225M | 15.364M | -15.625M | -35.878M | 82.96M |
| Begin Period Cash Flow | 105.933M | 90.569M | 106.194M | 142.072M | 59.112M |
| End Period Cash Flow | 75.708M | 105.933M | 90.569M | 106.194M | 142.072M |
| Total Cash From Operating Activities | -40.17M | -39.144M | -39.021M | -42.677M | -27.732M |
| Depreciation | 0.756M | 0.619M | 0.522M | 0.412M | 0.168M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -0.098M | -1.124M | -4.026M | -3.077M | -0.537M |
| Sale Purchase Of Stock | - | - | - | 0.771M | -0.001M |
| Other Cashflows From Financing Activities | 10.52M | 3.349M | 1.484M | 7.309M | 0.023M |
| Capital Expenditures | 0.58M | 1.361M | 0.591M | 0.685M | 1.183M |
| Change In Working Capital | 1.001M | 0.949M | -4.805M | -5.573M | -1.582M |
| Other Non Cash Items | 0.327M | 0.203M | 0.158M | 0.025M | 0.229M |
| Free Cash Flow | -40.75M | -40.505M | -39.612M | -43.362M | -28.915M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 684121 |
| 2. | iShares Russell 2000 ETF | 2 months ago | 387017 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 205267 |
| 4. | Silvercrest U.S. Small Cap Growth | 2 months ago | 171296 |
| 5. | Fidelity Small Cap Index | 4 months ago | 154347 |
| 6. | Mairs & Power Small Cap Composite | 5 months ago | 142456 |
| 7. | State St Russell Sm/Mid Cp® Indx SL Cl I | 2 months ago | 128200 |
| 8. | iShares Russell 2000 Growth ETF | 2 months ago | 125705 |
| 9. | Russell 2000 Equity Index Fund B | 5 months ago | 102451 |
| 10. | Fidelity Extended Market Index | 3 months ago | 95548 |
| 11. | Vanguard Russell 2000 ETF | 2 months ago | 79260 |
| 12. | Extended Equity Market Fund E | 5 months ago | 53872 |
| 13. | Extended Equity Market Fund B | 5 months ago | 53872 |
| 14. | Blackrock Extended Mkt Fund CF | 3 months ago | 53670 |
| 15. | Bridgeway Ultra-Small Company Market | 5 months ago | 49600 |
| 16. | Extended Equity Market Fund K | 2 months ago | 45698 |
| 17. | State St Russell Sm Cap® Indx SL Cl I | 3 months ago | 41900 |
| 18. | iShares Micro-Cap ETF | 2 months ago | 39796 |
| 19. | NT R2000 Index Fund - NL | 2 months ago | 35469 |
| 20. | Schwab Small Cap Index | 2 months ago | 34960 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Johnson & Johnson | 5 months ago | 4024861 |
| 2. | NEA Management Company, LLC | 5 months ago | 2026083 |
| 3. | Vanguard Group Inc | 5 months ago | 1120663 |
| 4. | BlackRock Inc | 8 months ago | 1015688 |
| 5. | Balyasny Asset Management LLC | 5 months ago | 814943 |
| 6. | Silvercrest Asset Management Group LLC | 5 months ago | 634639 |
| 7. | Morgan Stanley - Brokerage Accounts | 8 months ago | 431551 |
| 8. | Parkman Healthcare Partners LLC | 5 months ago | 413018 |
| 9. | Geode Capital Management, LLC | 5 months ago | 403949 |
| 10. | Citadel Advisors Llc | 5 months ago | 305503 |
| 11. | State Street Corp | 8 months ago | 295391 |
| 12. | Jane Street Group LLC | 5 months ago | 225349 |
| 13. | GSA Capital Partners LLP | 5 months ago | 183531 |
| 14. | Bank of America Corp | 8 months ago | 180425 |
| 15. | FourWorld Capital Management LLC | 5 months ago | 180000 |
| 16. | The Goldman Sachs Group Inc | 5 months ago | 177598 |
| 17. | Tudor Investment Corp Et AL | 5 months ago | 157260 |
| 18. | UBS Group AG | 8 months ago | 151323 |
| 19. | Northern Trust Corp | 8 months ago | 149284 |
| 20. | Mairs & Power Inc | 5 months ago | 142456 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...